Citadel Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
Other funds holding RYTM
BBA
Citadel Advisors's RYTM Position: Q3 2026 in Review
Citadel Advisors reduced its Rhythm Pharmaceuticals (RYTM) stake by 75% in Q3 2026, selling an estimated $101M and leaving 316,973 shares worth $30.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2104.
Citadel Advisors first reported a position in RYTM in Q4 2017 and has held it in 27 quarters since. The position peaked at $140M in Q2 2026. 333 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.
- Citadel Advisors held 316,973 shares of Rhythm Pharmaceuticals worth $30.2M as of Q3 2026.
- Citadel Advisors sold 946,679 Rhythm Pharmaceuticals shares in Q3 2026, an estimated $101M.
- Rhythm Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #2104 holding.
- Citadel Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 27 quarters since.
- Citadel Advisors's Rhythm Pharmaceuticals position peaked at $140M in Q2 2026.
- 333 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.